)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
ACADIA Pharmaceuticals (ACAD) investor relations material
ACADIA Pharmaceuticals Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary18 Nov, 2025
Strategic vision and growth
Aims for global biotech leadership in neurological and rare diseases, leveraging core franchises and expanding globally through 2038.
Focuses on precision medicine, biomarker-driven trials, AI/data innovation, and patient empowerment to enhance development and commercialization.
Plans expansion into endocrine, metabolic, nephrology, cardiovascular, and immunology therapeutic areas.
Emphasizes global reach, with a strong presence in Europe, Japan, and other regions.
Expects 2025 revenues to exceed $1 billion, with peak potential for current products estimated at $1.5–2 billion.
Commercial portfolio highlights
NUPLAZID leads in Parkinson's disease psychosis, with over 93,000 patients treated, a 25% U.S. market share among those treated with atypical antipsychotics, and patent protection through 2030.
Q3 NUPLAZID sales reached $177.5 million, up 21% year-over-year, with new prescriptions growing 23% and a 30% U.S. field force expansion planned by Q1 2026.
DAYBUE, the first approved Rett syndrome treatment, has treated over 2,000 U.S. patients since 2023, with strong persistency and real-world evidence supporting long-term efficacy.
Q3 DAYBUE sales exceeded $100 million, with international demand driving name patient supply programs in the EU, Israel, Middle East, and Latin America.
Strategic shift to community-based prescribing for DAYBUE, with 74% of Q3 prescriptions from community doctors and EU approval decision expected Q1 2026.
Pipeline and innovation
Pipeline risk-adjusted potential estimated at $2.5 billion, with peak potential up to $11 billion if all programs succeed.
ACP-204, a next-generation 5-HT2A agonist, targets Alzheimer's and Lewy body dementia psychosis, with phase II/III RADIANT trial enrolling globally and top-line results expected mid-2026.
ACP-211 for major depressive disorder aims to address unmet needs with minimal monitoring; phase II trial to enroll 153 patients, starting Q4 2025.
ACP-711 for essential tremor is in phase I, with phase II planned for Q4 2026, targeting a U.S. population of up to 7 million.
ACP-271, a GPR88 agonist, will enter first-in-human studies in Q1 2026, targeting tardive dyskinesia and Huntington's disease.
What are key risks to pipeline peak potential?
How to sustain NUPLAZID growth beyond 2038?
ACP-204: How will it transform ACADIA?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next ACADIA Pharmaceuticals earnings date
Citi Annual Global Healthcare Conference 20252 Dec, 2025
Next ACADIA Pharmaceuticals earnings date
Citi Annual Global Healthcare Conference 20252 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
ACADIA Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies addressing central nervous system disorders. The company offers treatments for conditions such as Parkinson’s disease psychosis and other neurological diseases. ACADIA operates within the healthcare sector, concentrating on innovative solutions for underserved medical needs. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage